Psoriatic Arthritis: Joint and Cutaneous Inflammation

Psoriatic arthritis (PsA) is a chronic inflammatory disease that combines arthritis, enthesitis, dactylitis, and spondylitis with cutaneous manifestations of psoriasis — in a unified pathophysiological spectrum mediated by T cells, IL-17, and IL-23. It affects 20%–30% of patients with cutaneous psoriasis, with peak onset between 30 and 50 years and no sex predominance. It is a potentially erosive and disabling disease when not adequately treated.

PsA shares pathophysiological mechanisms with cutaneous psoriasis — particularly the IL-23/IL-17 pathway — which creates potential interest for complementary approaches that may act on both joint and cutaneous manifestations. Some biopsy studies have reported modulation of this pathway after acupuncture at BL-17 and SP-10 — preliminary findings that require confirmation.

20–30%
Psoriasis evolves to PsA
Higher risk in nail, scalp, and intergluteal psoriasis
10 years
Mean diagnostic delay
PsA frequently underdiagnosed in patients with psoriasis
21%
Additional improvement in PASI with acupuncture
Cutaneous benefit additive to biologic (J Rheumatol, 2022)
67%
Resolution of dactylitis with acupuncture
In affected digits after 8 weeks of treatment

Conventional Treatment of Psoriatic Arthritis

PsA treatment requires addressing both joint and cutaneous manifestations — with most biologics being effective in both domains.

Therapeutic Options in PsA

DrugTargetEfficacy (ACR20)Cutaneous (PASI75)
NSAIDsCOX-1/2Symptomatic (pain/inflammation)No cutaneous effect
MethotrexateAntiproliferative (DMARD)41% ACR20PASI75 in 40%
Anti-TNF-α (adalimumab, etanercept)TNF-α57%–58% ACR20PASI75 in 50%–65%
Anti-IL-17 (secukinumab, ixekizumab)IL-17A54%–57% ACR20PASI75 in 70%–80%
Anti-IL-23 (guselkumab, risankizumab)IL-2356%–64% ACR20PASI75 in 75%–85%
Anti-IL-12/23 (ustekinumab)IL-12 and IL-2342% ACR20PASI75 in 60%

Mechanisms of Action in Psoriatic Arthritis

Acupuncture acts on both domains of PsA — joint and cutaneous — through mechanisms that converge on the central inflammatory pathways of the disease.

Mechanisms of Action by Domain

  1. 1. Joint Domain — Analgesia and Reduction of Synovitis

    LI-4 + LR-3 (Four Gates) activate the descending inhibitory pain pathways (PAG → raphe). Local periarticular points with EA at 2 Hz reduce synovitis through inhibition of prostaglandin release. DAS28 reduced by 0.9 points — clinically significant in PsA.

  2. 2. Cutaneous Domain — Hypothesis of IL-17/IL-23 Modulation via BL-17 and SP-10

    BL-17 (Geshu) and SP-10 (Xuehai) are the points classically used in dermatological approaches in traditional reasoning. Some biopsy studies report reduction of IL-17 and IL-23 in psoriasis plaques after acupuncture at these points — preliminary findings suggesting an immunological modulation mechanism, although on a much smaller clinical scale than that of specific biologics.

  3. 3. Dactylitis — Needling of the "Sausage Digit"

    Dactylitis is the most specific manifestation of PsA — involving digital synovitis + enthesitis + tenosynovitis. Peritendinous needling of the digital flexor sheath with EA at 2 Hz reduces edema and pain. The Ba Feng point (extra — between metatarsals on the dorsum of the foot) is especially effective for toe dactylitis.

  4. 4. Enthesitis — Peritendinous Needling

    Achilles enthesitis: KI-3 + BL-60 with needling 2–3 mm from the insertion. Plantar fascia enthesitis: SP-1 + BL-61 perilesional. EA at 2 Hz on the affected tendon promotes controlled microscarring and local reduction of prostaglandins and pro-inflammatory cytokines.

For Arthritis and Pain

  • • LI-4 + LR-3 — systemic analgesia
  • • ST-36 + SP-6 — anti-inflammatory
  • • LI-11 — heat/inflammation
  • • Local points by affected joint
  • • Ba Feng / Ba Xie for dactylitis

For Cutaneous Psoriasis

  • • BL-17 — point of influence on the blood
  • • SP-10 — "sea of blood", dermatoses
  • • LU-7 — skin (lung meridian)
  • • GV-14 — systemic heat
  • • DO NOT needle over an active psoriatic plaque

Scientific Evidence

The evidence for PsA is of smaller volume than for AS or RA, but the results point to real benefit, especially in the cutaneous domain when added to conventional treatment.

Clinical Results — Acupuncture in Psoriatic Arthritis

OutcomeResultVersusQuality
VAS arthralgia (0–10)−2.8 ptsMTX alone: −1.9 ptsLow-Moderate
DAS28 (joint activity)−0.9 pts—Low-Moderate
PASI (cutaneous psoriasis)−4.2 pts (+21% over biologic)Biologic aloneLow
Dactylitis (resolution per digit)67% resolution40% MTX aloneLow (1 RCT)
Quality of life (PsAQoL)+4.8 pts—Low

Clinical Protocol in Psoriatic Arthritis

Protocol by Dominant Phenotype

  1. Initial Assessment

    DAS28, PASI (cutaneous psoriasis), count of dactylitic and enthesitic joints. Biologic or DMARD in use. Photosensitivity (caution with post-session UV in patients with photosensitive psoriasis). Contraindication: do not needle over active plaques — Koebner phenomenon.

  2. Integrated Protocol (Joint + Cutaneous)

    Two sessions/week. Fixed protocol: BL-17 + SP-10 (cutaneous), LI-11 + ST-36 (anti-inflammatory), LI-4 + LR-3 (analgesic). Joint protocol: local points in affected joints, Ba Feng for dactylitis. EA at 2 Hz in joints with active synovitis. Enthesitis: peritendinous needling with EA.

  3. Coordination with Dermatologist/Rheumatologist

    Monitor PASI and DAS28 monthly. Communicate results to the responsible specialist. Therapy adjustments (phototherapy, biologic, DMARD) are decided by the specialist on an individualized basis — acupuncture complements, it does not replace. No drug interactions described with DMARDs or biologics.

When to Seek Medical Acupuncture in PsA

Priority Indications

  • • Mild-to-moderate PsA without yet an indication for biologic
  • • Persistent dactylitis despite DMARD
  • • Achilles or plantar enthesitis resistant to treatment
  • • PsA + moderate cutaneous psoriasis — dual approach
  • • Residual arthralgia in patients on biologic
  • • Patient who refuses biologic out of fear of immunosuppression

Specific Contraindications

  • • Never needle over active psoriatic plaques (Koebner)
  • • PsA with acute uveitis: treat the eye first
  • • Severe arthritis mutilans: prioritize biologic — acupuncture only as adjuvant
  • • Severe immunosuppression (high-dose biologic): hygienic precautions

Frequently Asked Questions

Frequently Asked Questions